Pan Cancer T

Foundation date



#Biotechnology - other


Pan Cancer T is a biotech spin-out that builds further on 20 years of pioneering in adoptive cell therapy developed in the laboratories of Erasmus MC. We intend to lead the fight against solid cancers through T cell receptor (TCR) gene engineered T-cell therapy. Especially, those solid cancers for which there are limited treatment options and a poor prognosis.

Upcoming events

Latest news

  • Mithra announces topline results for COVID-19 Phase II Study

    1 day ago

  • Biocartis announces restart of its high-throughput cartridge manufacturing line

    Thursday September 23rd 2021

  • Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer

    Wednesday September 22nd 2021